About
Contact
Help
Sending publications
How to publish
Advanced Search
View Item 
  •   Home
  • Facultad de Medicina
  • Artículos de revistas
  • View Item
  •   Home
  • Facultad de Medicina
  • Artículos de revistas
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse byCommunities and CollectionsDateAuthorsTitlesSubjectsThis CollectionDateAuthorsTitlesSubjects

My Account

Login to my accountRegister
Biblioteca Digital - Universidad de Chile
Revistas Chilenas
Repositorios Latinoamericanos
Tesis LatinoAmericanas
Tesis chilenas
Related linksRegistry of Open Access RepositoriesOpenDOARGoogle scholarCOREBASE
My Account
Login to my accountRegister

Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve the ARTE (aspirin versus aspirin plus clopidogrel following transcatheter aortic valve implantation) randomized clinical trial

Artículo
Thumbnail
Open/Download
IconAspirin-Versus-Aspirin-Plus.pdf (203.7Kb)
Access note
Acceso a solo metadatos
Publication date
2017
Metadata
Show full item record
Cómo citar
Rodes Cabau, Josep
Cómo citar
Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve the ARTE (aspirin versus aspirin plus clopidogrel following transcatheter aortic valve implantation) randomized clinical trial
.
Copiar
Cerrar

Author
  • Rodes Cabau, Josep;
  • Masson, Jean Bernard;
  • Welsh, Robert C.;
  • García del Blanco, Bruno;
  • Pelletier, Marc;
  • Webb, John G.;
  • Al Qoofi, Faisal;
  • Genereux, Philippe;
  • Maluenda Razeto, Gabriel;
  • Thoenes, Martin;
Abstract
OBJECTIVES The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death. BACKGROUND Few data exist on the optimal antithrombotic therapy following TAVR. METHODS This was a randomized controlled trial comparing aspirin (80 to 100 mg/day) plus clopidogrel (75 mg/day) (dual antiplatelet therapy [DAPT]) versus aspirin alone (single-antiplatelet therapy [SAPT]) in patients undergoing TAVR with a balloon-expandable valve. The primary endpoint was the occurrence of death, myocardial infarction (MI), stroke or transient ischemic attack, or major or life-threatening bleeding (according to Valve Academic Research Consortium 2 definitions) within the 3 months following the procedure. The trial was prematurely stopped after the inclusion of 74% of the planned study population. RESULTS A total of 222 patients were included, 111 allocated to DAPT and 111 to SAPT. The composite of death, MI, stroke or transient ischemic attack, or major or life-threatening bleeding tended to occur more frequently in the DAPT group (15.3% vs. 7.2%, p = 0.065). There were no differences between groups in the occurrence of death (DAPT, 6.3%; SAPT, 3.6%; p = 0.37), MI (DAPT, 3.6%; SAT, 0.9%; p = 0.18), or stroke or transient ischemic attack (DAPT, 2.7%; SAPT, 0.9%; p = 0.31) at 3 months. DAPT was associated with a higher rate of major or life-threatening bleeding events (10.8% vs. 3.6% in the SAPT group, p = 0.038). There were no differences between groups in valve hemodynamic status post-TAVR. CONCLUSIONS This small trial showed that SAPT (vs. DAPT) tended to reduce the occurrence of major adverse events following TAVR. SAPT reduced the risk for major or life-threatening events while not increasing the risk for MI or stroke. Larger studies are needed to confirm these results. (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation: The ARTE Trial [ARTE], NCT01559298; Aspirin Versus Aspirin + Clopidogrel as Antithrombotic Treatment Following TAVI [ARTE], NCT02640794) (C) 2017 by the American College of Cardiology Foundation.
Patrocinador
Edwards Lifesciences / Foundation of the Research Center of the Quebec Heart Lung Institute / AstraZeneca / Amgen Bayer / Janssen Bristol-Myers Squibb-Pfizer / Boehringer Ingelheim
Indexation
Artículo de publicación ISI
Identifier
URI: https://repositorio.uchile.cl/handle/2250/148050
DOI: 10.1016/j.jcin.2017.04.014
Quote Item
Jacc-Cardiovascular Interventions Vol.10 (13): 1357-1365
Collections
  • Artículos de revistas

Related items

Showing items related by title, author, creator and subject.

  • Artículountranslated
    Reconsidering the role of cyclooxygenase inhibition in the chemotherapeutic value of NO-releasing aspirins ... 
    Martin-Martin, Antonia; Rivera-Dictter, Andrés; Muñoz-Uribe, Matías; López-Contreras, Freddy; Pérez-Laines, Jorge; Molina-Berríos, Alfredo; López-Muñoz, Rodrigo (MDPI AG, 2019)
    Nitric oxide-releasing aspirins (NO-aspirins) are aspirin derivatives that are safer than the parent drug in the gastrointestinal context and have shown superior cytotoxic effects in several cancer models. Despite the ...
  • Artículountranslated
    Effects of aspirin on rat fetuses with reduction of uterine perfusion pressure Efectos de la aspirina en ... 
    Conei, Daniel; Gutiérrez, Ditsa Cáceres; Haverbeck, Michael; Fierro, Roberto; Veuthey, Carlos; Del Sol, Mariano; Rauco, Mariana Rojas (Universidad de la Frontera, 2019)
    Preeclampsia (PE) is a hypertensive disorder induced by pregnancy where there is a reduction in the uterine perfusion pressure. Research supports the use of low dose aspirin (LDAAS) and its usefulness in the prevention of ...
  • Artículountranslated
    Characterization of a novel antibiofilm effect of nitric oxide-releasing aspirin (NCX-4040) on Candida ... 
    Madariaga Venegas, Francisco; Fernández Soto, Roberto; Duarte, Luisa; Suárez, Nicole; Delgadillo, Daniela; Jara Sandoval, José; Fernández Ramires, Ricardo; Urzúa Orellana, Blanca; Molina Berríos, Alfredo Enrique (Public Library Science, 2017-05-11)
    Candida albicans biofilms play a key role in denture stomatitis, one of the most common oral pathologies in elderly people. Because biofilms are highly resistant to antifungals, new pharmacological strategies are needed. ...
xmlui.footer.title
31 participating institutions
More than 73,000 publications
More than 110,000 topics
More than 75,000 authors
Published in the repository
  • How to publish
  • Definitions
  • Copyright
  • Frequent questions
Documents
  • Dating Guide
  • Thesis authorization
  • Document authorization
  • How to prepare a thesis (PDF)
Services
  • Digital library
  • Chilean academic journals portal
  • Latin American Repository Network
  • Latin American theses
  • Chilean theses
Dirección de Servicios de Información y Bibliotecas (SISIB)
Universidad de Chile

© 2020 DSpace
  • Access my account